Drawn to diabetes tech, Pfizer inks deal for BioRexis

Pfizer is buying BioRexis Pharmaceutical for an undisclosed amount. BioRexis uses protein engineering technology in its work developing new therapies for diabetes. The biotech is developing long-acting GLP-1 receptor agonists for type 2 diabetes.

"Through this acquisition, we are investing in a company with an exciting new technology and potential new product candidates in diabetes," said Edmund P. Harrigan, M.D., senior vice president, worldwide licensing and new business development for Pfizer. "This is an example of how we are pursuing compelling science outside our walls in order to deliver new healthcare solutions to customers and patients."

- check out the release on the buyout

PLUS: Bioengineering researchers at UC San Diego have assembled a virtual human metabolic network that will give researchers a new way to hunt for better treatments for hundreds of human metabolic disorders--from diabetes to high levels of cholesterol in the blood. Report

Related Articles:
What's next for Pfizer? Report
Pfizer cuts 10,000 jobs. Report
Researchers probe chemical link to diabetes cure. Report